Glycemic changes in women with type 1 diabetes during their menstrual cycle

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This observational study aims to investigate glycemic fluctuations in women with type 1 diabetes throughout their menstrual cycle. By utilizing continuous glucose monitoring (CGM) data, the study will analyze insulin requirements and glycemic variations in a large cohort of women. The research focuses on understanding how hormonal changes during the menstrual cycle may affect insulin sensitivity and overall glycemic control. Participants will be required to share their CGM data and maintain a record of their menstrual cycles using a smartphone or tablet.

Why it matters

Who can join: the full rules

Inclusion Criteria:

1. Females aged 18 to 50 living in Canada.
2. Clinical diagnosis of type 1 diabetes or latent autoimmune diabetes in adults (LADA) for at least one year.
3. Using insulin pump therapy, multiple daily injections or automated insulin delivery systems for at least 3 months.
4. Using a continuous glucose monitoring (CGM) system.
5. Having at least one menses in the last 40 days.
6. Accepting to share CGM data with the research team and if applicable insulin pump data.This access will be limited to the study period.
7. Having a smartphone or tablet to follow menstrual cycles.
8. Stable weight (less than 5% variation in the last 3 months).

Exclusion Criteria:

1. Using a hormonal contraception method that eliminates menses (Depo Provera, progestin intrauterine device, extented-cycle regimen with birth control pill)
2. Using regular insulin (Entuzity U500, Novolin ge Toronto or Humulin R).
3. Clinically significant nephropathy (eGFR \< 30 ml/min/1.73m2, planned or on dialysis) or neuropathy (e.g., known uncontrolled gastroparesis) as judged by the investigator.
4. Recent (\< 6 months) acute macrovascular event (e.g., acute coronary syndrome or cardiac surgery).
5. Anticipated therapeutic change (including change of insulin type and/or type of CGM sensor, insulin pump or AID (automated insulin device) system) between admission and end of the study.
6. Anticipated change in contraception method or plan to begin or stop a contraceptive method.
7. Anticipated need to use acetaminophen during the study period at a dose above 1g every 6 hours.
8. Pregnancy (ongoing or current attempt to become pregnant)
9. Breastfeeding
10. Uncontrolled thyroid disease (TSH should be in target range and treatment stable for at least 6 weeks).
11. Severe hypoglycemic episode within two weeks of screening
12. Severe hyperglycemic episodes requiring hospitalization in the last 3 months.
13. Current use of glucocorticoid medication (except low stable dose and inhaled steroids and stable adrenal insufficiency treatment e.g., Cortef®)
14. Agents affecting gastric emptying (Motilium®, Victoza®, Ozempic®, Trulicity®, Byetta® and Symlin®) as well as oral anti-diabetic agents (Metformin, Prandase®, DPP-4 inhibitors) unless at a stable dose for 3 months and without anticipated change during the study.
15. Current use of SGLT-2 inhibitors unless at a stable dose for at least 3 months, without anticipated change during the study and appropriate ketone testing is performed.
16. Other serious medical illnesses which likely interfere with study participation or with the ability to complete the study by the judgment of the investigator.
17. Anticipation of a significant change in exercise or diet regimen between admission and end of the study (i.e., starting or stopping an organized sport; planned significant diet change).
18. Anticipated radiologic examination incompatible with CGM wear for more than 10 days between admission and end of the study (e.g., repeated MRI).
19. In the opinion of the investigator, a participant who is unable or unwilling to complete the study.
20. If taking medication for hypothyroidism, no change of dose (Levothyroxin) in the last 6 weeks.

Where it's running

• Institut de recherches cliniques de Montréal
  Montreal, Quebec, Canada Recruiting

Study contacts

• Principal investigator: Rémi Rabasa-Lhoret — Institut de Recherches Cliniques de Montreal
• Study coordinator: Anne Bonhoure
• Email: anne.bonhoure@ircm.qc.ca
• Phone: 514-987-5500

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Continuous Glucose Monitor Accuracy and Safety in Adults with Type 1 Diabetes

  This study tests a new real-time CGM system in adults with type 1 diabetes to see if its readings match venous blood glucose measurements.

  Recruiting SiBionics, Co, Ltd · Zibo, Shandong · NCT07745244

• Thrive With Type 1 Diabetes: A Behavioral Program to Improve Glucose and Sleep

  A behavioral program is being tested to see if it helps adults with type 1 diabetes better manage their sleep and glucose targets.

  Recruiting at 2 sites Emory University · Atlanta, Georgia and 1 other locations · NCT07522866

• Cardiometabolic effects of non-nutritive sweeteners in Type 1 diabetes

  This study tests whether non-nutritive sweeteners in a 12-ounce cherry Gatorade drink affect blood sugar control and cardiovascular markers in teens and young adults with Type 1 diabetes.

  Recruiting Medical College of Wisconsin · Milwaukee, Wisconsin · NCT07434544

• Wearable continuous glucose and ketone monitor for adults with type 1 diabetes

  This trial will test if a new wearable device can continuously and accurately measure glucose and ketone levels in adults with type 1 diabetes.

  Recruiting at 2 sites Henan University of Science and Technology · Shijiazhuang, Hebei and 1 other locations · NCT07139808

• Tirzepatide for obesity in people with type 1 diabetes

  This trial will test whether tirzepatide helps adults with type 1 diabetes and obesity lose weight and is safe for them.

  Recruiting Phase 4 Dasman Diabetes Institute · Kuwait City, Sharq · NCT07096908

• New real-time continuous glucose monitor accuracy and safety in adults with type 1 diabetes

  This project will test a new real-time continuous glucose monitor to see if its sensor readings match lab venous plasma (YSI) measurements in adults with type 1 diabetes.

  Recruiting Henan University of Science and Technology · Luoyang, Henan · NCT07092761

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.